Pricing Log in Create free account
Saturday 7 November 2026 Export MGTX’s income statement to Excel — free account

MeiraGTx Holdings PLC

MGTX Healthcare Biotechnology

MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024.

Revenue
+8,608.6%
EPS
+466.7%
Free cash flow
+13.1%
Total debt
+28.6%

Quarter to June 2026, against a year earlier

8.99 0.48 +5.64%
Market cap
$817.3M
P/E
11.8×
Fwd P/E
30.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.39
Beneish M
−3.01
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 4.68
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 2 1 — 2 1 — 2 —
Insider Ownership 19.46%

Capital & Financial Ratios $m

Size
Market Cap 817.32
Revenue ttm 397.50
Net income ttm 78.93
Free cash flow ttm 10.12
Net debt Q (43.08)
Valuation
P/E 11.83
Forward P/E 30.30
Price / sales 2.07
Forward P/S Powerpack
Price / FCF 81.19
Price / book 3.81
Financial health
Current ratio Q 3.76 (at or above 1.5: strong)
Debt / equity Q 0.46 (at or below 0.5: strong)
Interest coverage Q 69.66
Growth
Revenue growth Q +8,608.59% (above 0%: growing)
Operating income growth Q +645.68% (above 0%: growing)
EPS, this year +121.13% (at or above 15%: strong)
EPS, next year A −683.81% (below 0%: weak)
Revenue, next year A +314.17% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +5.92%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 19.6×; over the ten years it ranged from 2.0× in 2026 to 65.9× in 2023.
P/S against its own 10 years 0.12%
10-year low 10-year high
P/B against its own 10 years 70.62%
10-year low 10-year high
EV/Sales against its own 10 years 0.12%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 130 104 66 143
Receivables 23 10 18 44
Inventory — 0 — —
Other 1 3 2 27
160 124 92 218
2023 2024 2025 Q'26
Payables 16 24 10 12
ST’ Debt — — — —
Other 1 1 50 15
67 61 123 58

Compound Annual Growth %

10y 5y 3y
Sales — 39.22% 72.27%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.39 Actual 1.71

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.50 −0.62 Miss by 0.12
Q4 FY25 −0.60 0.19 Beat by 0.79
Q1 FY26 −0.43 −0.57 Miss by 0.14
Q2 FY26 −0.39 1.71 Beat by 2.10
Q3 FY26 −0.46 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.57) 1.71 — — —
’25 (0.51) (0.48) (0.62) 0.19 (1.42)
’24 (0.32) (0.76) (0.55) (0.50) (2.12)
’23 (0.62) (0.53) (0.74) 0.32 (1.49)
’22 (0.70) (0.76) (0.83) (0.58) (2.87)
’21 (0.54) (0.46) (0.59) (0.22) (1.80)
’20 (0.43) (0.69) (0.17) (0.25) (1.54)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 321 — — —
’25 2 4 0 75 81
’24 1 0 11 21 33
’23 3 4 5 2 14
’22 6 11 5 (5) 16
’21 5 5 7 21 38
’20 4 2 5 4 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 18 (39) — — —
’25 (37) (44) (12) 47 (46)
’24 (37) (19) (25) (23) (104)
’23 (37) (29) (24) (15) (105)
’22 (8) (28) (21) (16) (73)
’21 9 (21) (17) 19 (11)
’20 (12) (13) (9) (30) (64)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 16 (39) — — —
’25 (39) (45) (13) 46 (50)
’24 (38) (21) (26) (24) (109)
’23 (46) (34) (28) (18) (126)
’22 (21) (42) (31) (25) (118)
’21 5 (27) (29) (6) (57)
’20 (16) (16) (15) (38) (87)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 13 16 38 16 14 33 81 398 +35.3% 337 67 155 +24.0%
Gross margin, % 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 28.51 94.05 97.95 +94.1 pt
EBT (20) (31) (83) (55) (58) (80) (130) (84) (148) (114) 81 +21.5%
EBT margin, % 0.00 0.00 0.00 (411.87) (372.63) (211.03) (814.16) (599.46) (444.10) (140.31) 20.45 (140.3) pt
Net income (20) (31) (83) (55) (58) (80) (130) (84) (148) (114) 79 +21.5%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.40 0.41 0.85 0.35 0.25 0.48 1.01 4.35 n/m
Earnings (2.47) (3.62) (4.47) (1.65) (1.54) (1.80) (2.87) (1.49) (2.12) (1.42) 0.76 (6.0%)
Cash flow (1.79) (2.11) (3.11) 0.60 (1.70) (0.24) (1.62) (1.87) (1.50) (0.58) 0.15 (11.8%)
Capex (0.32) (1.23) (0.59) (0.27) (0.61) (1.05) (1.00) (0.36) (0.07) (0.05) (0.04) (19.5%)
Free cash flow (2.12) (3.34) (3.70) 0.33 (2.31) (1.29) (2.61) (2.22) (1.57) (0.62) 0.11 (12.7%)
Book value (2.14) (5.53) 4.28 5.75 6.32 4.20 2.61 2.45 0.97 (0.07) 2.36 (31.4%)
Shares, m 8 9 19 33 38 44 45 56 70 80 84 +29.2%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.83 0.0
P/S — — — 49.95 36.70 27.79 18.39 29.54 12.78 7.86 2.07 26.1
P/B — — — 3.48 2.39 5.65 2.49 3.00 6.27 0.00 3.81 3.3
EV/Sales — — — 34.47 24.50 24.68 16.68 26.36 11.86 7.66 1.96 20.9
EV/FCF — — — 41.41 (4.49) (16.36) (2.25) (2.94) (3.61) (12.45) 76.93 (0.1)
Cash, $m
Cash, $m Operating cash flow (14) (18) (59) 20 (64) (11) (73) (105) (104) (46) 14 +13.9%
Capex (3) (11) (11) (9) (23) (46) (45) (20) (5) (4) (4) +4.0%
Free cash flow (17) (29) (70) 11 (87) (57) (118) (126) (109) (50) 10 +12.8%
Balance, $m
Balance, $m Working capital 13 (10) 59 220 218 115 72 93 63 (31) 160 n/m
Net debt (17) (9) (68) (206) (190) (117) (27) (44) (30) (16) (43) (0.9%)
Shareholders’ equity (17) (47) 81 191 239 185 118 138 68 (6) 216 (11.4%)
Returns, %
Returns, % ROA (80.87) (131.60) (137.96) (26.02) (16.87) (23.27) (40.61) (26.06) (49.55) (44.42) 26.54 +36.4 pt
ROIC 0.00 0.00 (375.89) 0.00 (80.27) (66.82) (80.28) (91.44) (274.50) 0.00 66.60 0.0 pt
ROE 60.68 98.76 (502.59) (40.28) (27.01) (37.53) (85.52) (65.67) (143.48) (368.19) 72.22 (428.9) pt
People
People Employees — 59 68 157 219 296 358 425 381 403 — +27.1%
Revenue/emp, $m — 0.00 0.00 0.08 0.07 0.13 0.04 0.03 0.09 0.20 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

MeiraGTx Holdings PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LTGO Latigo Biotherapeutics Inc $862.6M — — — n/m — — 0.00% Compare
ANRO Alto Neuroscience, Inc. $858.2M — (loss-making) — — n/m −43.41% (below 0%: shrinking) — 0.00% Compare
RIGL Rigel Pharmaceuticals, Inc. $853.9M 2.4× 16.4× +16.45% (above 0%: growing) −54.84% (below 0%: shrinking) +43.90% (above 0%: growing) 86.67% 21.15% Compare
SNDX Syndax Pharmaceuticals, Inc. $843.6M — (loss-making) — (loss-making) +81.59% (above 0%: growing) n/m +61.43% (above 0%: growing) 83.20% (50.30%) Compare
AKTS Aktis Oncology, Inc. $826.0M — (loss-making) — (loss-making) — n/m −12.77% (below 0%: shrinking) 100.00% (853.99%) Compare
CRVS Corvus Pharmaceuticals, Inc. $818.5M — (loss-making) — — n/m −171.31% (below 0%: shrinking) 0.00% 0.00% Compare
MGTX MeiraGTx Holdings PLC $817.3M 11.8× 30.3× +8,608.59% (above 0%: growing) n/m +13.06% (above 0%: growing) 97.77% 76.04%
PRME Prime Medicine, Inc. $807.1M — (loss-making) — (loss-making) +3.50% (above 0%: growing) n/m +4.40% (above 0%: growing) 100.00% (3,750.87%) Compare
ALMS Alumis Inc. $780.9M — (loss-making) — (loss-making) −37.66% (below 0%: shrinking) n/m +23.59% (above 0%: growing) 100.00% (8,956.38%) Compare
Median of peers $834.8M — — +9.98% — +4.40% 93.34% (25.15%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 8.33m 11.82m 120.71
2024 6.88m 6.05m 93.40
2023 6.34m 5.84m 107.67

Ownership

Directors and executive officers, together 7.40%
Sanofi 13.20%
Perceptive Advisors, LLC 12.60%
Rubric Capital Management LP 8.40%
Johnson & Johnson Innovation-JJDC, Inc. 7.20%
Adage Capital Partners, L.P. 5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

MeiraGTx Holdings PLC (MGTX) Latest News

27 Oct

Impact 3 · · GlobeNewswire

23 Sep

Impact 3 ·

14 Aug

Impact 4 ·
Impact 4 · · GlobeNewswire
Impact 3 ·
Impact 3 · · Zacks

13 Aug

Impact 3 ·

7 Jul

Impact 4 ·

20 May

Impact 3 · · Insider Monkey

14 May

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

5 May

Impact 3 · · Zacks

22 Apr

Impact 4 · · Zacks

16 Apr

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

14 Apr

Impact 3 · · GlobeNewswire

30 Mar

Impact 3 · · Simply Wall St.

26 Mar

Impact 4 · · Zacks
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat

3 Feb

Impact 4 · · PR Newswire

16 Dec

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

13 Nov

Impact 3 · · GlobeNewswire

10 Nov

Impact 4 · · GlobeNewswire

5 Nov

Impact 4 · · Zacks

22 Oct

Impact 3 · · Zacks

7 Oct

Impact 3 · · GlobeNewswire

15 Aug

Impact 3 · · Simply Wall St.

9 Jul

Impact 4 ·
stockrow.com/MGTX · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com